Which has higher earnings & valuation, IMVT or BHVN?

Immunovant is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is IMVT or BHVN more profitable?

Immunovant's return on equity of -68.46% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -68.46% -62.28% Biohaven N/A -866.46% -137.99%

Does the media prefer IMVT or BHVN?

In the previous week, Immunovant had 4 more articles in the media than Biohaven. MarketBeat recorded 9 mentions for Immunovant and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat Immunovant's score of 0.39 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, TGTX or BHVN?

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 12.36 $447.18M $2.74 18.16 Biohaven N/A N/A -$738.82M -$5.67 N/A

Is TGTX or BHVN more profitable?

TG Therapeutics has a net margin of 55.22% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 55.22% 73.49% 34.14% Biohaven N/A -866.46% -137.99%

Does the media prefer TGTX or BHVN?

In the previous week, TG Therapeutics had 29 more articles in the media than Biohaven. MarketBeat recorded 34 mentions for TG Therapeutics and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat TG Therapeutics' score of 0.10 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, BHVN or PCVX?

Vaxcyte is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A Vaxcyte N/A N/A -$766.63M -$7.63 N/A

Is BHVN or PCVX more profitable?

Vaxcyte's return on equity of -37.56% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Vaxcyte N/A -37.56% -33.62%

Does the media favor BHVN or PCVX?

In the previous week, Vaxcyte had 14 more articles in the media than Biohaven. MarketBeat recorded 19 mentions for Vaxcyte and 5 mentions for Biohaven. Vaxcyte's average media sentiment score of 0.78 beat Biohaven's score of 0.55 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, IBRX or BHVN?

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $165.79M 48.84 -$351.40M -$0.97 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is IBRX or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Biohaven N/A -866.46% -137.99%

Does the media prefer IBRX or BHVN?

In the previous week, ImmunityBio had 13 more articles in the media than Biohaven. MarketBeat recorded 18 mentions for ImmunityBio and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat ImmunityBio's score of 0.34 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or BHVN?

In the previous week, Rhythm Pharmaceuticals had 19 more articles in the media than Biohaven. MarketBeat recorded 24 mentions for Rhythm Pharmaceuticals and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat Rhythm Pharmaceuticals' score of 0.53 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Biohaven 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biohaven (BHVN) Competitors

$14.67 +0.25 (+1.74%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$14.54 -0.13 (-0.89%)

As of 08/7/2026 07:34 PM Eastern

Compare

BHVN vs. IMVT, TGTX, PCVX, IBRX, and RYTM

Should you buy Biohaven stock or one of its competitors? MarketBeat compares Biohaven with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biohaven include Immunovant (IMVT), TG Therapeutics (TGTX), Vaxcyte (PCVX), ImmunityBio (IBRX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "biotechnology" industry.

How does Biohaven compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Immunovant is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Immunovant has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Immunovant presently has a consensus price target of $44.00, suggesting a potential upside of 10.14%. Biohaven has a consensus price target of $21.63, suggesting a potential upside of 47.40%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immunovant's return on equity of -68.46% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-68.46%	-62.28%
Biohaven	N/A	-866.46%	-137.99%

In the previous week, Immunovant had 4 more articles in the media than Biohaven. MarketBeat recorded 9 mentions for Immunovant and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat Immunovant's score of 0.39 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biohaven beats Immunovant on 9 of the 14 factors compared between the two stocks.

How does Biohaven compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, TG Therapeutics had 29 more articles in the media than Biohaven. MarketBeat recorded 34 mentions for TG Therapeutics and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat TG Therapeutics' score of 0.10 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 55.22% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Biohaven	N/A	-866.46%	-137.99%

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	12.36	$447.18M	$2.74	18.16
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

TG Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

TG Therapeutics currently has a consensus price target of $63.00, indicating a potential upside of 26.61%. Biohaven has a consensus price target of $21.63, indicating a potential upside of 47.40%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

TG Therapeutics beats Biohaven on 9 of the 16 factors compared between the two stocks.

How does Biohaven compare to Vaxcyte?

Biohaven (NYSE:BHVN) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Vaxcyte is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

Biohaven presently has a consensus target price of $21.63, indicating a potential upside of 47.40%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 48.10%. Given Vaxcyte's higher probable upside, analysts clearly believe Vaxcyte is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Biohaven has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, Vaxcyte had 14 more articles in the media than Biohaven. MarketBeat recorded 19 mentions for Vaxcyte and 5 mentions for Biohaven. Vaxcyte's average media sentiment score of 0.78 beat Biohaven's score of 0.55 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte's return on equity of -37.56% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Vaxcyte	N/A	-37.56%	-33.62%

88.8% of Biohaven shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Biohaven beats Vaxcyte on 8 of the 14 factors compared between the two stocks.

How does Biohaven compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

ImmunityBio presently has a consensus target price of $14.20, indicating a potential upside of 85.86%. Biohaven has a consensus target price of $21.63, indicating a potential upside of 47.40%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$165.79M	48.84	-$351.40M	-$0.97	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

In the previous week, ImmunityBio had 13 more articles in the media than Biohaven. MarketBeat recorded 18 mentions for ImmunityBio and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat ImmunityBio's score of 0.34 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Biohaven	N/A	-866.46%	-137.99%

ImmunityBio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ImmunityBio beats Biohaven on 9 of the 16 factors compared between the two stocks.

How does Biohaven compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Biohaven (NYSE:BHVN) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Rhythm Pharmaceuticals had 19 more articles in the media than Biohaven. MarketBeat recorded 24 mentions for Rhythm Pharmaceuticals and 5 mentions for Biohaven. Biohaven's average media sentiment score of 0.55 beat Rhythm Pharmaceuticals' score of 0.53 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Biohaven	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals presently has a consensus target price of $142.44, suggesting a potential upside of 23.18%. Biohaven has a consensus target price of $21.63, suggesting a potential upside of 47.40%. Given Biohaven's higher probable upside, analysts clearly believe Biohaven is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

88.8% of Biohaven shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Biohaven has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Rhythm Pharmaceuticals' return on equity of -159.87% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Biohaven	N/A	-866.46%	-137.99%

Rhythm Pharmaceuticals has higher revenue and earnings than Biohaven. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	33.03	-$196.54M	-$3.11	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Summary

Rhythm Pharmaceuticals beats Biohaven on 9 of the 16 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.21B	$3.69B	$7.02B	$24.19B
Dividend Yield	N/A	3.76%	2.58%	3.70%
P/E Ratio	-2.59	9.02	271.11	29.20
Price / Sales	N/A	1,266.32	590.37	167.26
Price / Cash	N/A	102.35	71.81	33.74
Price / Book	37.62	18.10	13.25	6.87
Net Income	-$738.82M	-$13.25M	$3.45B	$1.06B
7 Day Performance	8.72%	6.24%	4.67%	2.91%
1 Month Performance	-12.36%	-3.50%	-1.28%	2.94%
1 Year Performance	-0.34%	61.28%	77.33%	20.40%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	3.4177 of 5 stars	$14.67 +1.7%	$21.63 +47.4%	-0.3%	$2.21B	N/A	N/A	239	News Coverage Upcoming Earnings Gap Up
IMVT Immunovant	1.7221 of 5 stars	$38.51 -0.3%	$42.11 +9.4%	+158.4%	$7.97B	N/A	N/A	120	News Coverage Earnings Report Analyst Forecast
TGTX TG Therapeutics	3.905 of 5 stars	$46.17 -11.3%	$58.50 +26.7%	+86.3%	$7.96B	$616.29M	16.14	290	Earnings Report Analyst Forecast Analyst Revision High Trading Volume
PCVX Vaxcyte	2.7433 of 5 stars	$53.53 -1.0%	$86.00 +60.7%	+94.2%	$7.81B	N/A	N/A	160	News Coverage Earnings Report Analyst Upgrade Insider Trade
IBRX ImmunityBio	2.3682 of 5 stars	$7.15 -0.3%	$14.20 +98.6%	+213.1%	$7.51B	$113.29M	N/A	590	News Coverage Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors

BHVN vs. IMVT, TGTX, PCVX, IBRX, and RYTM

How does Biohaven compare to Immunovant?

Summary

How does Biohaven compare to TG Therapeutics?

Summary

How does Biohaven compare to Vaxcyte?

Summary

How does Biohaven compare to ImmunityBio?

Summary

How does Biohaven compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biohaven (BHVN) Competitors

BHVN vs. IMVT, TGTX, PCVX, IBRX, and RYTM

How does Biohaven compare to Immunovant?

Which has higher earnings & valuation, IMVT or BHVN?

Which has more volatility and risk, IMVT or BHVN?

Do analysts rate IMVT or BHVN?

Do insiders and institutionals have more ownership in IMVT or BHVN?

Is IMVT or BHVN more profitable?

Does the media prefer IMVT or BHVN?

Summary

How does Biohaven compare to TG Therapeutics?

Does the media prefer TGTX or BHVN?

Is TGTX or BHVN more profitable?

Do institutionals and insiders believe in TGTX or BHVN?

Which has stronger valuation and earnings, TGTX or BHVN?

Which has more volatility & risk, TGTX or BHVN?

Do analysts recommend TGTX or BHVN?

Summary

How does Biohaven compare to Vaxcyte?

Which has preferable valuation & earnings, BHVN or PCVX?

Do analysts rate BHVN or PCVX?

Which has more volatility & risk, BHVN or PCVX?

Does the media favor BHVN or PCVX?

Is BHVN or PCVX more profitable?

Do institutionals & insiders hold more shares of BHVN or PCVX?

Summary

How does Biohaven compare to ImmunityBio?

Do analysts rate IBRX or BHVN?

Which has preferable earnings & valuation, IBRX or BHVN?

Does the media prefer IBRX or BHVN?

Is IBRX or BHVN more profitable?

Which has more volatility and risk, IBRX or BHVN?

Do insiders and institutionals believe in IBRX or BHVN?

Summary

How does Biohaven compare to Rhythm Pharmaceuticals?

Does the media prefer RYTM or BHVN?

Do analysts prefer RYTM or BHVN?

Which has more volatility and risk, RYTM or BHVN?

Do insiders & institutionals have more ownership in RYTM or BHVN?

Is RYTM or BHVN more profitable?

Which has preferable valuation & earnings, RYTM or BHVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools